Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | CFTR | P13569 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPRB | P23467 | 1/20 | 0.49 |
| ▸ | PTPRE | P23469 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467640 | 0.91 | CFTR (0.58) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5447386 | 0.89 | NPSR1 (0.60) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5467138 | 0.86 | CFTR (0.62) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5451710 | 0.85 | CFTR (0.58) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5458989 | 0.84 | CFTR (0.60) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5463020 | 0.84 | CFTR (0.55) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5454147 | 0.83 | CFTR (0.59) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5453359 | 0.82 | CFTR (0.64) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5452378 | 0.82 | CFTR (0.58) | SMN1; SMN2NPSR1CFTRKDM4EFLT3 | |
| SCHEMBL5445049 | 0.82 | CFTR (0.60) | SMN1; SMN2CFTRKDM4EFLT3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | SMN1; SMN2 2157/4885NPSR1 3733/4885CFTR 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.